




European Monitoring Centre
for Drugs and Drug Addiction

Opioid substitution treatment in Europe: access, quality and prevention of diversion

Getting the balance right



Update

Thank you!

1st draft, parts missing, findings and conclusions

Clarifications

Scientific publication

Guiding principles to get the balance right





Access

Prevention

Thoughts


Strong points

Weak points




Models


Figure 8 Opioid substitution treatment provision models in the EU




Model 1. Outpatient specialised provision model – primarily observed in Eastern EU countries, but also in Italy



Model 2. Outpatient mixed specialised and non-specialised provision model – primarily observed in Western European countries, but also in the Czech Republic and Croatia.



Model 3. Mixed outpatient and inpatient provision model.



Patients per doctors

Table 2 Number of OST prescribing doctors per target population (POUs) and per OST patients in 6 Member States

Country	Number of prescribing doctors	POUs per prescribing doctor	OST patients per prescribing doctor
Ireland	351	not known	28.2
France	30000	7.6	3.6
Germany	2590	57-67	30
Austria	563-641	55.1	31.2
Poland	25 centres (2 doctors per centre)	580 (290/doctor)	95.2 (47.6/doctor)
Finland	not known	not known	not known



Dispensing practices


Table 3 Dispensing practices of OST medications in 6 Member States

Country	Where do all or almost all OST clients currently in OST obtain their medication from?		If the dispensing is mostly pharmacy-based, does the OST client obtain his/her medication:	
	Community-based pharmacies	Treatment provider	From one specifically assigned pharmacy:	Or, he/she can obtain it from any pharmacy (where OST is available):
Finland	✗	✓	✓*	✗
Germany	✓	✓*	✓*	✓
Poland	✗	✓	✗	✗
Austria	✓	✗	✗	✓
Ireland	✓	✗	✓	✗
France	✓	✗	✓	✗




Waiting times

PL update
1-2 weeks



Coverage



NB: Data displayed as point estimates and uncertainty intervals.

Need to include LT, IE (EDR 2015) and SK (2016) in the graph and update text. FI to be inserted based on input. }

Here a box on the methodologies on estimating the total number of POUs in a country



Denominator of OST coverage

While it could be argued that people already receiving OST could not be included in the overall estimate of the problem opioid using population as a majority of these are not and should not be considered as problematic opioid users anymore. However, as with any other medical chronic disorder requiring long-term treatment, the calculation of the coverage of a medical treatment applies to the overall population in need of continuous, long-term treatment whether they are currently in or out of treatment.



Denominator of OST coverage

Stable in treatment
(incl. OST + drug
free)

Non stable in and
out of treatment



Utility of the denominator (In need of treatment)

Percentage of high-risk opioid users receiving drug treatment (estimate)






Table 4: Treatment entrants citing opioids as primary drug: percentage

Country	Heroin	Methadone	Buprenorphine	Fentanyl	Other
Belgium	87%	7%	0%	0%	5%
Bulgaria	87%	9%	0%	0%	4%
Czech Republic	48%	7%	30%		16%
Denmark	53%	25%	6%		15%
Germany	51%	28%	10%		11%
Estonia	6%	15%		77%	2%
Ireland	87%	3%	0%	0%	10%
Greece	92%	0%	3%	0%	5%
Spain	91%	4%	0%	0%	5%
France	72%	7%	11%	0%	9%
Croatia	94%	2%	3%	0%	1%
Italy	97%	1%	0%		2%
Cyprus	68%		1%		31%
Latvia	87%	2%	1%	0%	10%
Lithuania	96%	2%	0%	0%	2%
Luxembourg	99%				1%
Hungary	77%	8%	0%	0%	15%
Malta	100%				
Netherlands	75%	11%	0%	0%	14%
Austria	80%	2%	3%	0%	15%
Poland	72%	4%	2%	1%	21%
Portugal	97%	0%	1%		2%
Romania	92%	4%	0%	0%	4%
Slovenia	91%	3%	5%	0%	2%
Slovakia	74%	0%	1%	5%	19%
Finland	1%	2%	84%	1%	12%
United Kingdom	85%	4%	5%	0%	7%
Turkey	99%	0%	0%	0%	1%
Norway					



Table 5 Treatments demands for misuse of OST medications as a percentage of all OST prescribed in a country

Country	Treatment entrants for misuse of methadone and buprenorphine	OST clients	Treatment entrants for misuse as a % of all OST patients
Austria	97	17599	1%
Belgium	225	16681	1%
Bulgaria	140	3423	4%
Croatia	321	5061	6%
Cyprus	2	252	1%
Czech Republic	632	4000	16%
Denmark	193	6268	3%
Estonia	40	1166	3%
Finland	293	3000	10%
France	2569	168840	2%
Germany	13349	77200	17%
Greece	91	10082	1%
Hungary	12	669	2%
Ireland	135	9917	1%
Italy	305	60047	1%
Latvia	13	609	2%
Lithuania	64	596	11%
Luxembourg	0	1078	0%
Malta	0	1026	0%
Netherlands	141	7421	2%
Norway	0	7498	0%
Poland	90	2564	4%
Portugal	11	17011	1%
Romania	40	547	7%
Slovakia	10	600	2%
Slovenia	17	3261	1%
Spain	489	61859	1%
United Kingdom	5172	142085	4%



Burden of OST deaths?

- Figure: Proportion DRD mention of OST medication and of heroin mention
- Figure DRD mention of OST medication per General Population rate
- Figure DRD mention of OST medication per OST prescribed rate
- Figure DRD mention of OST medication per POU rate?
- BOX: Safety profile of methadone versus buprenorphine



Index of access?

Index of prevention of misuse?

